Drug Approval | September 01, 2022
Biological E. announces CDSCO recommendation of its infant’s vaccine
Subject Expert Committee(SEC) of Central Drugs Standard Control Organization (CDSCO)
Subject Expert Committee(SEC) of Central Drugs Standard Control Organization (CDSCO)
This launch builds upon Hikma’s leading position as one of the largest US providers of nasally administered medicines used for treating seasonal allergies and advances its objective of growing its specialty business in the US
Philips AI-powered interventional and diagnostic smart systems enhances diagnostic confidence, drive greater efficiency, and improve patient outcomes
With the receipt of the EIR, the inspection stands successfully closed.
~96% decline reported in Malaria cases in Madhya Pradesh, due to public-private-people partnership
OrderPoint was designed as an advanced DTR solution from its first release in 2016.
Phase 1 dose-escalation study to be conducted at clinical sites in the U.S., the UK, Australia, and the Philippines
The company has reported total income of Rs. 450.26 crores during the period ended June 30, 2022.
The company has reported total income of Rs. 70.59 crores during the period ended June 30, 2022.
Company appoints five new independent directors to reconstituted board
Subscribe To Our Newsletter & Stay Updated
